Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide

DOI PDF 被引用文献9件
  • Dilip Unnikrishnan
    From the Our Lady of Mercy Cancer Center and Division of Cardiology, Our Lady of Mercy Medical Center, Bronx, NY, and New York Medical College, Valhalla, NY.
  • Janice P. Dutcher
    From the Our Lady of Mercy Cancer Center and Division of Cardiology, Our Lady of Mercy Medical Center, Bronx, NY, and New York Medical College, Valhalla, NY.
  • Nikita Varshneya
    From the Our Lady of Mercy Cancer Center and Division of Cardiology, Our Lady of Mercy Medical Center, Bronx, NY, and New York Medical College, Valhalla, NY.
  • Richard Lucariello
    From the Our Lady of Mercy Cancer Center and Division of Cardiology, Our Lady of Mercy Medical Center, Bronx, NY, and New York Medical College, Valhalla, NY.
  • Marietta Api
    From the Our Lady of Mercy Cancer Center and Division of Cardiology, Our Lady of Mercy Medical Center, Bronx, NY, and New York Medical College, Valhalla, NY.
  • Susan Garl
    From the Our Lady of Mercy Cancer Center and Division of Cardiology, Our Lady of Mercy Medical Center, Bronx, NY, and New York Medical College, Valhalla, NY.
  • Peter H. Wiernik
    From the Our Lady of Mercy Cancer Center and Division of Cardiology, Our Lady of Mercy Medical Center, Bronx, NY, and New York Medical College, Valhalla, NY.
  • Salvatore Chiaramida
    From the Our Lady of Mercy Cancer Center and Division of Cardiology, Our Lady of Mercy Medical Center, Bronx, NY, and New York Medical College, Valhalla, NY.

抄録

<jats:p>Arsenic trioxide is used in clinical trials in the treatment of relapsed and resistant cases of acute promyelocytic leukemia. Adverse effects from arsenic in these studies have been multisystemic. Arsenic is known to cause corrected QT-interval prolongation and T-wave changes, but the potential for serious ventricular arrhythmias is less well understood. Torsades de pointes, a form of ventricular tachycardia, has been reported with arsenic poisoning but not at therapeutic doses used in protocols for hematologic malignancies. We describe 3 patients in whom this arrhythmia developed while they were treated with arsenic trioxide. Early recognition of the arrhythmia or correction of contributory factors is important because arsenic induced ventricular arrhythmias are known to be resistant to most chemical methods and electrical cardioversion.</jats:p>

収録刊行物

  • Blood

    Blood 97 (5), 1514-1516, 2001-03-01

    American Society of Hematology

被引用文献 (9)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ